We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
+11.45%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$76M
AUM Growth
-$11.1M
(-13%)
Cap. Flow
+$112M
Cap. Flow
% of AUM
147.28%
Top 10 Holdings %
Top 10 Hldgs %
38.02%
Holding
408
New
159
Increased
53
Reduced
54
Closed
131
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$3.17M |
| 2 |
K
Kellanova
K
|
+$2.19M |
| 3 |
FL
Foot Locker
FL
|
+$2.04M |
| 4 |
General Mills
GIS
|
+$1.95M |
| 5 |
lululemon athletica
LULU
|
+$1.74M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$9.7M |
| 2 |
JPMorgan Chase
JPM
|
+$3.58M |
| 3 |
Gilead Sciences
GILD
|
+$3.38M |
| 4 |
Constellation Brands
STZ
|
+$2.74M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.66% |
| 2 | Consumer Staples | 16.16% |
| 3 | Consumer Discretionary | 9.31% |
| 4 | Communication Services | 3.38% |
| 5 | Materials | 2.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
PUT
General Mills
GIS
$20.3B
| $689K | 0.91% |
124,600
+9,200
| +8% | +$562K |
|
|
GWPH
27
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $688K | 0.91% |
56,600
-25,000
| -31% | -$3.07M |
|
28
Invesco QQQ Trust
QQQ
$466B
| $679K | 0.89% |
+5,130
| New | +$655K |
|
|
DD
29
CALL
DELISTED
Du Pont De Nemours E I
DD
| $677K | 0.89% |
140,400
+30,500
| +28% | +$2.37M |
|
|
LUMO
30
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $669K | 0.88% |
3,085
+2,974
| +2,679% | +$425K |
|
|
TSRO
31
PUT
DELISTED
TESARO, Inc.
TSRO
| $666K | 0.88% |
22,700
-8,500
| -27% | -$1.38M |
|
32
Intuitive Surgical
ISRG
$122B
| $656K | 0.86% |
+7,704
| New | +$609K |
|
|
CASC
33
DELISTED
Cascadian Therapeutics, Inc.
CASC
| $594K | 0.78% |
143,429
-34,400
| -19% | -$145K |
|
34
Larimar Therapeutics
LRMR
$384M
| $568K | 0.75% |
10,161
-833
| -8% | -$41.4K |
|
35
Children's Place
PLCE
$65.8M
| $552K | 0.73% |
+4,600
| New | +$485K |
|
36
TransDigm Group
TDG
$67.9B
| $541K | 0.71% |
+2,458
| New | +$587K |
|
37
IBM
IBM
$200B
| $528K | 0.7% |
+3,173
| New | +$532K |
|
38
SCYNEXIS
SCYX
$42.4M
| $508K | 0.67% |
2,299
+800
| +53% | +$201K |
|
39
Vertex Pharmaceuticals
VRTX
$123B
| $501K | 0.66% |
4,582
-4,966
| -52% | -$437K |
|
40
Microsoft
MSFT
$2.93T
| $500K | 0.66% |
+7,592
| New | +$487K |
|
|
CMRX
41
DELISTED
Chimerix, Inc.
CMRX
| $480K | 0.63% |
75,239
-130,027
| -63% | -$738K |
|
|
42
PUT
lululemon athletica
LULU
$13.2B
| $477K | 0.63% |
+31,600
| New | +$2.08M |
|
|
YHOO
43
DELISTED
Yahoo Inc
YHOO
| $464K | 0.61% |
10,000
| – | – |
|
44
PUT
Perrigo
PRGO
$1.48B
| $459K | 0.6% |
+19,200
| New | +$1.46M |
|
45
CALL
AbbVie
ABBV
$450B
| $455K | 0.6% |
141,900
+68,056
| +92% | +$4.28M |
|
46
CALL
Incyte
INCY
$23.4B
| $455K | 0.6% |
20,700
+5,700
| +38% | +$726K |
|
|
EBIX
47
DELISTED
Ebix Inc
EBIX
| $449K | 0.59% |
+7,335
| New | +$436K |
|
|
XLNX
48
DELISTED
Xilinx Inc
XLNX
| $406K | 0.53% |
+7,020
| New | +$413K |
|
49
Coca-Cola Europacific Partners
CCEP
$46.5B
| $404K | 0.53% |
10,729
+2,729
| +34% | +$95.2K |
|
|
BWLD
50
DELISTED
Buffalo Wild Wings, Inc.
BWLD
| $393K | 0.52% |
+2,573
| New | +$393K |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q1 2017 Portfolio in Review
As of Q1 2017, FT Options held 408 positions worth $76M, down 13% from $87.1M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
FT Options deployed $112M of net new capital in Q1 2017, opening 159 new positions and adding to 53 existing holdings. Its largest new stake was GW Pharmaceuticals Plc American Depositary Shares: 25,829 shares worth $3.12M.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, down from 45% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $9.7M trimmed.
- FT Options's largest Q1 2017 buy was GW Pharmaceuticals Plc American Depositary Shares: 25,829 shares worth $3.12M.
- FT Options added most to Kellanova in Q1 2017, an estimated $2.19M increase.
- FT Options's biggest Q1 2017 reduction was Regeneron Pharmaceuticals, cutting an estimated $9.7M.
- FT Options fully exited JPMorgan Chase in Q1 2017, selling an estimated $3.58M.
- FT Options's ten largest holdings make up 38% of its $76M portfolio in Q1 2017.
- FT Options opened 159 new positions and closed 131 in Q1 2017.
- FT Options's portfolio value fell 13% quarter-over-quarter to $76M.
Based on FT Options's 13F filing for Q1 2017, filed 12 May 2017.